Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
HealthBeacon PLC - Dublin-based digital therapeutics company developing project for managing injectable medications - Last Friday reported an increased interim loss but expects strong growth. Pretax loss in the first six months to June 30 widens to €6.2 million from €2.5 million. Revenue grows 59% to €867,000 from €545,000. Cost of sales widen to €780,000 from €232,000. Expects ten-fold increase in number of patients using its technology in 2024.
‘During the first half of 2022 we generated significant momentum, despite some meaningful global supply chain challenges, adding important new clients, new products, key hires and expanding our capabilities, infrastructure and routes to market,’ says Chief Executive Officer Jim Joyce.
Current stock price: €3.82
12-month change: down 35%
Copyright 2022 Alliance News Limited. All Rights Reserved.